دورية أكاديمية
The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design.
| العنوان: | The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. |
|---|---|
| المؤلفون: | Cousins MJ; Pain Management Research Institute, Royal North Shore Hospital, St. Leonards, New South Wales, Australia., Pickthorn K, Huang S, Critchley L, Bell G |
| المصدر: | Pain medicine (Malden, Mass.) [Pain Med] 2013 Apr; Vol. 14 (4), pp. 533-40. Date of Electronic Publication: 2013 Feb 25. |
| نوع المنشور: | Comparative Study; Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: published by Oxford University Press on behalf of the American Academy of Pain Medicine Country of Publication: England NLM ID: 100894201 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-4637 (Electronic) Linking ISSN: 15262375 NLM ISO Abbreviation: Pain Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2016- : Oxford, England : published by Oxford University Press on behalf of the American Academy of Pain Medicine Original Publication: Malden, MA : Blackwell Science, Inc., c2000- |
| مواضيع طبية MeSH: | Anesthetics, Local/*therapeutic use , Lidocaine/*therapeutic use , Neuralgia, Postherpetic/*drug therapy , Protein Kinase C-epsilon/*antagonists & inhibitors , Protein Kinase Inhibitors/*therapeutic use, Aged ; Aged, 80 and over ; Anesthetics, Local/adverse effects ; Cross-Over Studies ; Double-Blind Method ; Female ; Humans ; Lidocaine/adverse effects ; Male ; Middle Aged ; Pain Measurement ; Peptides/therapeutic use ; Protein Kinase C-epsilon/adverse effects ; Sample Size ; Treatment Outcome |
| مستخلص: | Objective: Postherpetic neuralgia (PHN) occurs in approximately 10-20% of patients with herpes zoster, and the risk increases with age. In this clinical trial, we evaluated the analgesic properties of KAI-1678-an inhibitor of epsilon protein kinase C-in the treatment of neuropathic pain in patients with PHN. Design: The study was a three-treatment period, double-blind, randomized, placebo and active comparator crossover trial evaluating subcutaneous infusions of KAI-1678 (25 mg), placebo, and lidocaine hydrochloride (700 mg; active comparator). Patients: A total of 17 men and 6 women (N = 23) were enrolled after fulfilling diagnosis of PHN with pain persisting for ≥3 months after a segmental herpes zoster eruption. Patients had to have a mean average pain score of ≥4 points on an 11-point numerical rating scale (NRS; ranging from 0 to 10) based on at least three daily entries prior to participation in the subsequent treatment period. Results: Overall, administration of KAI-1678 was generally safe and well tolerated. However, compared with placebo, KAI-1678 did not improve clinical pain scores as recorded using the NRS (0-10). In contrast, subcutaneous infusions of lidocaine were associated with a significant reduction in pain intensity at the end of the infusion. Conclusions: We conclude that KAI-1678 is not efficacious as an acute analgesic for chronic neuropathic pain because of PHN. However, for the first time, the results demonstrate that subcutaneous infusions of lidocaine are effective in treating neuropathic pain. The results of lidocaine treatment also indicate that the crossover study design was adequate to detect a clinically meaningful response in this analgesia study. (Wiley Periodicals, Inc.) |
| المشرفين على المادة: | 0 (Anesthetics, Local) 0 (KAI-1678) 0 (Peptides) 0 (Protein Kinase Inhibitors) 98PI200987 (Lidocaine) EC 2.7.11.13 (Protein Kinase C-epsilon) |
| تواريخ الأحداث: | Date Created: 20130227 Date Completed: 20131105 Latest Revision: 20131121 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1111/pme.12058 |
| PMID: | 23438341 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1526-4637 |
|---|---|
| DOI: | 10.1111/pme.12058 |